WILMINGTON, Del.--(BUSINESS WIRE)--June 7, 2006--Incyte Corporation (Nasdaq:INCY - News) today announced that it has initiated a Phase I clinical trial of INCB13739, an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes.
